FDA approves Genpharm’s application for Zaleplon

PITTSBURGH The Food and Drug Administration has granted final approval for Mylan subsidiary Genpharm’s application for 5mg and 10mg Zaleplon Capsules, Mylan announced Monday.

Zaleplon Capsules are a generic version of King Pharmaceuticals’ Sonata Capsules, which treat insomnia. Mylan announced that it would begin marketing the capsules immediately under the Mylan Pharmaceuticals brand.

Sonata had sales of $88 million during the 12 months ending March 31, according to IMS Health data.